Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Back to Forecasting
CORT Forecast Markets
Corcept Therapeutics Incorporated
7
Active Markets
38%
Avg Probability
All Markets
7 markets
Will the FDA grant a resubmission path (not new-trial) for relacorilant Cushing's by 2026-06-30?
55%
Likely Yes
92% agreement
Jun 30, 2026
IG: 0.80
Will Lifyorli Year 1 US revenue annualize above $50M by the Q3 2026 10-Q?
38%
Likely No
92% agreement
Nov 15, 2026
IG: 0.72
Will CORT revise FY2026 revenue guidance below $900M by Q2 2026 earnings?
35%
Likely No
92% agreement
Aug 15, 2026
IG: 0.64
Will the Korlym scripts-vs-tablets gap narrow below 10 percentage points in the Q1 2026 10-Q?
50%
Likely No
92% agreement
May 15, 2026
IG: 0.60
Will a third-party ANDA on mifepristone be filed by year-end 2026?
25%
Likely No
93% agreement
Dec 31, 2026
IG: 0.56
Will Maduck or Mokari file a Form 4 sale below $40 by 2026-09-30?
35%
Likely No
93% agreement
Sep 30, 2026
IG: 0.48
Will MONARCH MASH Phase 2b hit its primary endpoint by year-end 2026?
28%
Likely No
94% agreement
Dec 31, 2026
IG: 0.48
Resolution Timeline
May 15, 2026
Will the Korlym scripts-vs-tablets gap narrow below 10 percentage points in the Q1 2026 10-Q?Prediction: 50%
Jun 30, 2026
Will the FDA grant a resubmission path (not new-trial) for relacorilant Cushing's by 2026-06-30?Prediction: 55%
Aug 15, 2026
Will CORT revise FY2026 revenue guidance below $900M by Q2 2026 earnings?Prediction: 35%
Nov 15, 2026
Will Lifyorli Year 1 US revenue annualize above $50M by the Q3 2026 10-Q?Prediction: 38%